{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:01Z","timestamp":1787020981887,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81670624"],"award-info":[{"award-number":["No.81670624"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Project from Jiangsu Commission of Health","award":["No. H2019062"],"award-info":[{"award-number":["No. H2019062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Diabetic nephropathy (DN) causes the vast proportion of excess mortality for patients with diabetes. Novel therapeutic approaches slowing down its incidence is still lacking. Psoralen is the major active ingredient of\n                      <jats:italic>Psoralea corylifolia Linn.<\/jats:italic>\n                      (PCL), which was used to treat a number of diseases. In this study, we aimed to investigate whether psoralen could alleviate DN using in vitro model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cell viability assay and immunofluorescence were used to evaluate the effect of psoralen on high glucose (HG)-stimulated human kidney HK-2 cells (48\u2009h). RT-qPCR was used to detect the expressions of miRNA in cells. Cell transfection, apoptosis assay, inflammatory cytokines detection and Western blot were further performed to explore the underlying molecular mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HG-induced toxicity of HK-2 cells was alleviated by psoralen. Meanwhile, the secretion of inflammatory cytokines and extracellular matrix (ECM) accumulation induced by HG in HK-2 cells were also decreased by psoralen. In addition, the expression of miR-874 in HK-2 cells was significantly upregulated by psoralen. Western blot assays indicated that psoralen could reverse HG-induced increase of TLR-4\/NF-\u03baB and Smad2 via upregulation of miR-874.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated that psoralen could significantly alleviate HG-induced HK-2 cell injury via upregulation of miR-874. In addition, HG-induced increase of TLR-4\/NF-\u03baB and Smad2 was revered by psoralen. Therefore, psoralen might serve as an agent for the treatment of DN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-020-00434-1","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T08:03:38Z","timestamp":1595405018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Psoralen alleviates high glucose-induced HK-2 cell injury by inhibition of Smad 2 signaling via upregulation of microRNA 874"],"prefix":"10.1186","volume":"21","author":[{"given":"Yongtao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"434_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.omtn.2018.07.012","volume":"12","author":"J Wang","year":"2018","unstructured":"Wang J, Pan J, Li H, Long J, Fang F, Chen J, et al. lncRNA ZEB1-AS1 Was Suppressed by p53 for Renal Fibrosis in Diabetic Nephropathy. Mol Ther Nucleic Acids. 2018;12:741\u201350. https:\/\/doi.org\/10.1016\/j.omtn.2018.07.012.","journal-title":"Mol Ther Nucleic Acids"},{"key":"434_CR2","doi-asserted-by":"publisher","first-page":"697010","DOI":"10.1155\/2015\/697010","volume":"2015","author":"S Toth-Manikowski","year":"2015","unstructured":"Toth-Manikowski S, Atta MG. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015:697010. https:\/\/doi.org\/10.1155\/2015\/697010.","journal-title":"J Diabetes Res"},{"issue":"4","key":"434_CR3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.32394\/rpzh.2018.0037","volume":"69","author":"K Nadolnik","year":"2018","unstructured":"Nadolnik K, Skrypnik D, Skrypnik K, Bogdanski P. Diabetic nephropathy in the elderly - clinical practice. Rocz Panstw Zakl Hig. 2018;69(4):327\u201334. https:\/\/doi.org\/10.32394\/rpzh.2018.0037.","journal-title":"Rocz Panstw Zakl Hig"},{"issue":"5\u20136","key":"434_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10557-017-6755-9","volume":"31","author":"C Magee","year":"2017","unstructured":"Magee C, Grieve DJ, Watson CJ, Brazil DP. Diabetic nephropathy: a tangled web to unweave. Cardiovasc Drugs Ther. 2017;31(5\u20136):579\u201392. https:\/\/doi.org\/10.1007\/s10557-017-6755-9.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"434_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3904\/kjim.2016.174","volume":"32","author":"Y Kim","year":"2017","unstructured":"Kim Y, Park CW. New therapeutic agents in diabetic nephropathy. Korean J Int Med. 2017;32(1):11\u201325. https:\/\/doi.org\/10.3904\/kjim.2016.174.","journal-title":"Korean J Int Med"},{"issue":"1\u20132","key":"434_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1900\/rds.2015.12.110","volume":"12","author":"K Tziomalos","year":"2015","unstructured":"Tziomalos K, Athyros VG. Diabetic nephropathy: new risk factors and improvements in diagnosis. Rev Diabetes Stud. 2015;12(1\u20132):110\u20138. https:\/\/doi.org\/10.1900\/rds.2015.12.110.","journal-title":"Rev Diabetes Stud"},{"issue":"2","key":"434_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/asn.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302\u20138. https:\/\/doi.org\/10.1681\/asn.2012070718.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"434_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/tri.12413","volume":"28","author":"S Stoumpos","year":"2015","unstructured":"Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and mortality after kidney transplantation. Transpl Int. 2015;28(1):10\u201321. https:\/\/doi.org\/10.1111\/tri.12413.","journal-title":"Transpl Int"},{"issue":"1","key":"434_CR9","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1080\/13880209.2017.1383484","volume":"55","author":"A Kassahun Gebremeskel","year":"2017","unstructured":"Kassahun Gebremeskel A, Wijerathne TD, Kim JH, Kim MJ, Seo CS, Shin HK, et al. Psoralea corylifolia extract induces vasodilation in rat arteries through both endothelium-dependent and -independent mechanisms involving inhibition of TRPC3 channel activity and elaboration of prostaglandin. Pharm Biol. 2017;55(1):2136\u201344. https:\/\/doi.org\/10.1080\/13880209.2017.1383484.","journal-title":"Pharm Biol"},{"key":"434_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3389\/fphar.2017.00876","volume":"8","author":"L Zhou","year":"2017","unstructured":"Zhou L, Tang J, Xiong X, Dong H, Huang J, Zhou S, et al. Psoralea corylifolia L. Attenuates Nonalcoholic Steatohepatitis in Juvenile Mouse. Front Pharmacol. 2017;8:876. https:\/\/doi.org\/10.3389\/fphar.2017.00876.","journal-title":"Front Pharmacol"},{"key":"434_CR11","doi-asserted-by":"publisher","first-page":"2160175","DOI":"10.1155\/2019\/2160175","volume":"2019","author":"L Ge","year":"2019","unstructured":"Ge L, Cheng K, Han J. A network pharmacology approach for uncovering the Osteogenic mechanisms of Psoralea corylifolia Linn. Evid Based Complement Alternat Med. 2019;2019:2160175. https:\/\/doi.org\/10.1155\/2019\/2160175.","journal-title":"Evid Based Complement Alternat Med"},{"key":"434_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.fitote.2013.06.016","volume":"90","author":"B Chopra","year":"2013","unstructured":"Chopra B, Dhingra AK, Dhar KL. Psoralea corylifolia L. (Buguchi) - folklore to modern evidence: review. Fitoterapia. 2013;90:44\u201356. https:\/\/doi.org\/10.1016\/j.fitote.2013.06.016.","journal-title":"Fitoterapia."},{"issue":"1","key":"434_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/13880209.2018.1501584","volume":"56","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Wu J, Zhou Y, Yin Y, Chen H. Effects of psoralen on the pharmacokinetics of anastrozole in rats. Pharm Biol. 2018;56(1):433\u20139. https:\/\/doi.org\/10.1080\/13880209.2018.1501584.","journal-title":"Pharm Biol"},{"key":"434_CR14","doi-asserted-by":"publisher","unstructured":"Seo E, Kang H, Oh YS, Jun HS. Psoralea corylifolia L. Seed Extract Attenuates Diabetic Nephropathy by Inhibiting Renal Fibrosis and Apoptosis in Streptozotocin-Induced Diabetic Mice. Nutrients. 2017;9(8). https:\/\/doi.org\/10.3390\/nu9080828.","DOI":"10.3390\/nu9080828"},{"issue":"1","key":"434_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7150\/ijbs.28830","volume":"15","author":"C Wang","year":"2019","unstructured":"Wang C, Al-Ani MK, Sha Y, Chi Q, Dong N, Yang L, et al. Psoralen protects chondrocytes, exhibits anti-inflammatory effects on Synoviocytes, and attenuates monosodium Iodoacetate-induced osteoarthritis. Int J Biol Sci. 2019;15(1):229\u201338. https:\/\/doi.org\/10.7150\/ijbs.28830.","journal-title":"Int J Biol Sci"},{"key":"434_CR16","doi-asserted-by":"publisher","first-page":"3524307","DOI":"10.1155\/2017\/3524307","volume":"2017","author":"S Chen","year":"2017","unstructured":"Chen S, Wang Y, Yang Y, Xiang T, Liu J, Zhou H, et al. Psoralen inhibited apoptosis of osteoporotic osteoblasts by modulating IRE1-ASK1-JNK pathway. Biomed Res Int. 2017;2017:3524307. https:\/\/doi.org\/10.1155\/2017\/3524307.","journal-title":"Biomed Res Int"},{"key":"434_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bcp.2018.06.017","volume":"155","author":"S Dewanjee","year":"2018","unstructured":"Dewanjee S, Bhattacharjee N. MicroRNA: a new generation therapeutic target in diabetic nephropathy. Biochem Pharmacol. 2018;155:32\u201347. https:\/\/doi.org\/10.1016\/j.bcp.2018.06.017.","journal-title":"Biochem Pharmacol"},{"issue":"13","key":"434_CR18","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2217\/imt-2019-0047","volume":"11","author":"J Wang","year":"2019","unstructured":"Wang J, Cui Z, Liu L, Zhang S, Zhang Y, Zhang Y, et al. MiR-146a mimic attenuates murine allergic rhinitis by downregulating TLR4\/TRAF6\/NF-kappaB pathway. Immunotherapy. 2019;11(13):1095\u2013105. https:\/\/doi.org\/10.2217\/imt-2019-0047.","journal-title":"Immunotherapy."},{"key":"434_CR19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fphar.2018.01187","volume":"9","author":"F Chen","year":"2018","unstructured":"Chen F, Zhu X, Sun Z, Ma Y. Astilbin inhibits high glucose-induced inflammation and extracellular matrix accumulation by suppressing the TLR4\/MyD88\/NF-kappaB pathway in rat glomerular Mesangial cells. Front Pharmacol. 2018;9:1187. https:\/\/doi.org\/10.3389\/fphar.2018.01187.","journal-title":"Front Pharmacol"},{"issue":"1","key":"434_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/jcp.26908","volume":"234","author":"T Yao","year":"2018","unstructured":"Yao T, Zha D, Gao P, Shui H, Wu X. MiR-874 alleviates renal injury and inflammatory response in diabetic nephropathy through targeting toll-like receptor-4. J Cell Physiol. 2018;234(1):871\u20139. https:\/\/doi.org\/10.1002\/jcp.26908.","journal-title":"J Cell Physiol"},{"issue":"3","key":"434_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000005879","volume":"96","author":"ZJ Xu","year":"2017","unstructured":"Xu ZJ, Shu S, Li ZJ, Liu YM, Zhang RY, Zhang Y. Liuwei Dihuang pill treats diabetic nephropathy in rats by inhibiting of TGF-\u03b2\/SMADS, MAPK, and NF-kB and upregulating expression of cytoglobin in renal tissues. Medicine. 2017;96(3):e5879. https:\/\/doi.org\/10.1097\/md.0000000000005879.","journal-title":"Medicine"},{"issue":"1 Supplement","key":"434_CR22","doi-asserted-by":"crossref","first-page":"213.10","DOI":"10.4049\/jimmunol.198.Supp.213.10","volume":"198","author":"HS Dreja","year":"2017","unstructured":"Dreja HS, Ayton J, Bruce D, Lochead J, Renshaw S, Parton L, et al. Knockout validation of antibodies to Ki67: a marker for cellular proliferation. J Immunol. 2017;198(1 Supplement):213.10 10.","journal-title":"J Immunol"},{"issue":"5","key":"434_CR23","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.3892\/etm.2019.7359","volume":"17","author":"S Yang","year":"2019","unstructured":"Yang S, Fei X, Lu Y, Xu B, Ma Y, Wan H. miRNA-214 suppresses oxidative stress in diabetic nephropathy via the ROS\/Akt\/mTOR signaling pathway and uncoupling protein 2. Exp Ther Med. 2019;17(5):3530\u20138. https:\/\/doi.org\/10.3892\/etm.2019.7359.","journal-title":"Exp Ther Med"},{"issue":"5","key":"434_CR24","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3892\/ijmm.2019.4325","volume":"44","author":"N Li","year":"2019","unstructured":"Li N, Wang LJ, Xu WL, Liu S, Yu JY. MicroRNA-379-5p suppresses renal fibrosis by regulating the LIN28\/let-7 axis in diabetic nephropathy. Int J Mol Med. 2019;44(5):1619\u201328. https:\/\/doi.org\/10.3892\/ijmm.2019.4325.","journal-title":"Int J Mol Med"},{"key":"434_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.26355\/eurrev_201902_17018","volume":"23","author":"SZ Zhang","year":"2019","unstructured":"Zhang SZ, Qiu XJ, Dong SS, Zhou LN, Zhu Y, Wang MD, et al. MicroRNA-770-5p is involved in the development of diabetic nephropathy through regulating podocyte apoptosis by targeting TP53 regulated inhibitor of apoptosis 1. Eur Rev Med Pharmacol Sci. 2019;23:1248\u201356. https:\/\/doi.org\/10.26355\/eurrev_201902_17018.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"434_CR26","doi-asserted-by":"publisher","first-page":"4728645","DOI":"10.1155\/2018\/4728645","volume":"2018","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Zhao S, Wu D, Liu X, Shi M, Wang Y, et al. MicroRNA-22 promotes renal Tubulointerstitial fibrosis by targeting PTEN and suppressing autophagy in diabetic nephropathy. J Diabetes Res. 2018;2018:4728645. https:\/\/doi.org\/10.1155\/2018\/4728645.","journal-title":"J Diabetes Res"},{"issue":"1","key":"434_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/0886022x.2018.1490322","volume":"40","author":"ZE Xia","year":"2018","unstructured":"Xia ZE, Xi JL, Shi L. 3,3\u2032-Diindolylmethane ameliorates renal fibrosis through the inhibition of renal fibroblast activation in vivo and in vitro. Ren Fail. 2018;40(1):447\u201354. https:\/\/doi.org\/10.1080\/0886022x.2018.1490322.","journal-title":"Ren Fail"},{"issue":"4","key":"434_CR28","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.3892\/mmr.2019.10613","volume":"20","author":"Y Huang","year":"2019","unstructured":"Huang Y, Hou Q, Su H, Chen D, Luo Y, Jiang T. miR-488 negatively regulates osteogenic differentiation of bone marrow mesenchymal stem cells induced by psoralen by targeting Runx2. Mol Med Rep. 2019;20(4):3746\u201354. https:\/\/doi.org\/10.3892\/mmr.2019.10613.","journal-title":"Mol Med Rep"},{"key":"434_CR29","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.2147\/cmar.S248094","volume":"12","author":"L Jin","year":"2020","unstructured":"Jin L, Ma XM, Wang TT, Yang Y, Zhang N, Zeng N, et al. Psoralen suppresses Cisplatin-mediated resistance and induces apoptosis of gastric adenocarcinoma by disruption of the miR196a-HOXB7-HER2 Axis. Cancer Manag Res. 2020;12:2803\u201327. https:\/\/doi.org\/10.2147\/cmar.S248094.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"434_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.22038\/ijbms.2019.37469.8939","volume":"23","author":"XF Lin","year":"2020","unstructured":"Lin XF, Jiang QL, Peng ZL, Ning YL, Luo YY, Zhao F, et al. Therapeutic effect of psoralen on muscle atrophy induced by tumor necrosis factor-\u03b1. Iran J Basic Med Sci. 2020;23(2):251\u20136. https:\/\/doi.org\/10.22038\/ijbms.2019.37469.8939.","journal-title":"Iran J Basic Med Sci"},{"issue":"5","key":"434_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097985","volume":"9","author":"J Ma","year":"2014","unstructured":"Ma J, Chadban SJ, Zhao CY, Chen X, Kwan T, Panchapakesan U, et al. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One. 2014;9(5):e97985. https:\/\/doi.org\/10.1371\/journal.pone.0097985.","journal-title":"PLoS One"},{"key":"434_CR32","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.2147\/dddt.S143805","volume":"11","author":"F Tang","year":"2017","unstructured":"Tang F, Hao Y, Zhang X, Qin J. Effect of echinacoside on kidney fibrosis by inhibition of TGF-beta1\/Smads signaling pathway in the db\/db mice model of diabetic nephropathy. Drug Design Dev Ther. 2017;11:2813\u201326. https:\/\/doi.org\/10.2147\/dddt.S143805.","journal-title":"Drug Design Dev Ther"},{"issue":"6","key":"434_CR33","first-page":"6828","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang Y, Lin C, Ren Q, Liu Y, Yang X. Astragaloside effect on TGF-\u03b21, SMAD2\/3, and \u03b1-SMA expression in the kidney tissues of diabetic KKAy mice. Int J Clin Exp Pathol. 2015;8(6):6828\u201334.","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"434_CR34","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3892\/ijmm.2017.3148","volume":"40","author":"W Zheng","year":"2017","unstructured":"Zheng W, Lin P, Ma Y, Shao X, Chen H, Chen D, et al. Psoralen promotes the expression of cyclin D1 in chondrocytes via the Wnt\/\u03b2-catenin signaling pathway. Int J Mol Med. 2017;40(5):1377\u201384. https:\/\/doi.org\/10.3892\/ijmm.2017.3148.","journal-title":"Int J Mol Med"},{"issue":"1","key":"434_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-016-0468-y","volume":"35","author":"X Wang","year":"2016","unstructured":"Wang X, Xu C, Hua Y, Sun L, Cheng K, Jia Z, et al. Exosomes play an important role in the process of psoralen reverse multidrug resistance of breast cancer. J Exp Clin Cancer Res. 2016;35(1):186. https:\/\/doi.org\/10.1186\/s13046-016-0468-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"434_CR36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bbrc.2011.01.021","volume":"405","author":"DZ Tang","year":"2011","unstructured":"Tang DZ, Yang F, Yang Z, Huang J, Shi Q, Chen D, et al. Psoralen stimulates osteoblast differentiation through activation of BMP signaling. Biochem Biophys Res Commun. 2011;405(2):256\u201361. https:\/\/doi.org\/10.1016\/j.bbrc.2011.01.021.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-020-00434-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-00434-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T13:22:32Z","timestamp":1696425752000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-00434-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-00434-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-19865\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-19865\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-19865\/v1","asserted-by":"object"}]},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"15 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}